Toth Financial Advisory Corp Increases Stock Position in Medtronic PLC $MDT

Toth Financial Advisory Corp raised its stake in shares of Medtronic PLC (NYSE:MDT) by 8.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,270 shares of the medical technology company’s stock after purchasing an additional 5,863 shares during the period. Toth Financial Advisory Corp’s holdings in Medtronic were worth $7,134,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Artisan Partners Limited Partnership lifted its position in Medtronic by 2.6% during the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after purchasing an additional 31,314 shares during the last quarter. SageView Advisory Group LLC increased its holdings in shares of Medtronic by 164.8% in the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock worth $2,305,000 after buying an additional 15,062 shares during the last quarter. CSM Advisors LLC raised its position in shares of Medtronic by 13.2% during the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock valued at $27,169,000 after buying an additional 33,167 shares in the last quarter. UMB Bank n.a. raised its position in shares of Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after buying an additional 54,898 shares in the last quarter. Finally, Applied Finance Capital Management LLC bought a new position in shares of Medtronic in the 3rd quarter valued at about $1,308,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Trading Down 0.0%

NYSE MDT opened at $86.61 on Friday. The company’s 50-day moving average price is $94.47 and its 200-day moving average price is $96.22. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The stock has a market cap of $111.19 billion, a PE ratio of 24.12, a PEG ratio of 2.24 and a beta of 0.75. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Analysts Set New Price Targets

A number of research analysts recently commented on MDT shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. Truist Financial decreased their price objective on Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a research report on Wednesday, February 18th. Sanford C. Bernstein raised their price objective on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. JPMorgan Chase & Co. dropped their target price on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Finally, Piper Sandler cut their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and an average target price of $109.85.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).